GHK-Cu across skin
GHK-Cu brings copper into the name. The hair trial adds another ingredient entirely; the skin studies ask what reached tissue and what changed.
Skin penetration
Copper applied as GHK-Cu both crossed removed human skin and remained in a dermal reservoir in a laboratory study. This is ex vivo work: the tissue came from a human body, but the experiment happened outside it. Copper movement was the outcome.
A later review of topical GHK describes poor passage through the stratum corneum, the outer skin barrier, as a central problem. It discusses chemical modifications and microneedle pretreatment among ways researchers have investigated improving entry. Those are experimental approaches, rather than instructions for a skin routine.
These findings can coexist. A particular skin preparation allowed researchers to quantify copper movement; the broader delivery literature still describes an obstacle. The preparation and the skin layers under study determine what the experiment can answer. I appreciate this precise location record: some copper crossed, some stayed, and a treatment claim still requires a separate measurement.
Small topical trials
Human skin studies gathered in the topical review and the earlier skin-regeneration review reported changes in skin appearance and signs of collagen production. Collagen gives skin structural support; elastin helps it stretch and spring back. The human studies were small, and the encouraging appearance findings need confirmation by other teams.
The hair trial deserves its full ingredient list. Over six months, 45 men with inherited hair loss received a combination containing GHK and 5-aminolevulinic acid or placebo. Hair counts increased more with the tested combination. No adverse events were reported in any group.
That is a finding about the combination. The study cannot isolate the contribution of GHK, and it tested a GHK-containing preparation rather than establishing an effect of pure GHK-Cu. A small trial reporting no adverse events also leaves uncommon and longer-term harms unresolved.
The hair mixture earns my caution because the study leaves each ingredient’s share unresolved.
Plasma origin and cellular activity
The origin reaches further back than the skin literature. GHK was first isolated from human plasma in 1973 as a factor that prompted aged liver tissue to synthesize proteins more like younger tissue. I had associated GHK with skin; its liver-tissue origin gives the history an unexpected breadth.
GHK is the free tripeptide, while GHK-Cu has copper bound to it. Skin products may identify the copper complex as Copper Tripeptide-1. The distinction matters when following a paper, because the literature includes work on both forms.
The gene-expression review describes changes in how cells use DNA instructions, including pathways associated with repair, protein disposal and resistance to chemical damage. These are cell and database findings. The appealing breadth of the proposed effects has run ahead of human tests of whole-body repair or slower ageing, and much of the foundational literature comes from a small group of authors. Confirmation by separate teams would strengthen the broader claims.
Irritation and wider use
People discussing topical copper peptides describe smoother, firmer or better-hydrated skin, alongside redness, itching, dryness and breakouts. Accounts of pigment changes disagree. These are anecdotal accounts, not clinical evidence, and they cannot establish either the cause of a change or its frequency.
Some accounts describe injected GHK-Cu and credit it with skin or recovery benefits. Injectable and systemic use remains unapproved, with no validated human pharmacokinetic basis: dependable data on how much reaches which tissues, how it is cleared and what repeated exposure does are missing.
The topical review also examines formulation stability. An ingredient can change or break down in a mixture before it reaches skin. This makes the finished preparation another research question, alongside penetration and local effects. No GHK-Cu medicine is approved to treat illness; its cosmetic history supplies much less information about systemic use.
The KPV delivery experiments take a related problem to the bowel, where protective carriers and a cell transporter play very different roles.